Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/mus.27375 http://scihub22266oqcxt.onion/10.1002/mus.27375 34287987!ä!34287987 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Muscle+Nerve 2021 ; 64 (4): 487-490 Nephropedia Template TP {{tp|p=34287987|t=2021. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1 |pdf=|usr=}}{{34287987}} gab.com Text Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1 JO: Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=34287987 #FOAvip INTRODUCTION/AIMS: There are currently three medications approved for spinal muscular atrophy (SMA), but the use of these medications in combination has not been well described. METHODS: This is a retrospective report of four cases of SMA treated with dual onasemnogene and risdiplam therapy at our institution. RESULTS: Following onasemnogene therapy, all four patients experienced a perceived plateau of therapeutic benefit, at which time daily risdiplam was started. Transient fatigue and weakness was seen in two patients following risdiplam initiation, but this resolved within 1 mo. One patient was hospitalized with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and post-viral pneumonia, weeks following risdiplam initiation. No other adverse effects related to onasemnogene and risdiplam combination therapy were identified and all patients experienced objective and subjective improvement. DISCUSSION: Combination therapy with onasemnogene and risdiplam in patients with SMA appears to be well-tolerated. Further large prospective trials are needed to determine whether dual therapy is more efficacious than monotherapy, and to identify rare adverse events that may occur with the use of combination therapy. Twit Text FOAVip Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1 ????Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=34287987 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34287987 #FOAvip English Wikipedia <ref>{{Cite pmid|34287987}}</ref> Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1 #MMPMID34287987 Oechsel KF; Cartwright MS Muscle Nerve 2021[Oct]; 64 (4): 487-490 PMID34287987show ga INTRODUCTION/AIMS: There are currently three medications approved for spinal muscular atrophy (SMA), but the use of these medications in combination has not been well described. METHODS: This is a retrospective report of four cases of SMA treated with dual onasemnogene and risdiplam therapy at our institution. RESULTS: Following onasemnogene therapy, all four patients experienced a perceived plateau of therapeutic benefit, at which time daily risdiplam was started. Transient fatigue and weakness was seen in two patients following risdiplam initiation, but this resolved within 1 mo. One patient was hospitalized with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and post-viral pneumonia, weeks following risdiplam initiation. No other adverse effects related to onasemnogene and risdiplam combination therapy were identified and all patients experienced objective and subjective improvement. DISCUSSION: Combination therapy with onasemnogene and risdiplam in patients with SMA appears to be well-tolerated. Further large prospective trials are needed to determine whether dual therapy is more efficacious than monotherapy, and to identify rare adverse events that may occur with the use of combination therapy. |Azo Compounds/*administration & dosage[MESH] |Biological Products/*administration & dosage[MESH] |Combined Modality Therapy/methods[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Genetic Therapy/methods[MESH] |Humans[MESH] |Infant[MESH] |Male[MESH] |Pyrimidines/*administration & dosage[MESH] |Recombinant Fusion Proteins/*administration & dosage[MESH] |Retrospective Studies[MESH]Combination therapy with onasemnogene and risdiplam in spinal muscular(epmc).pdf DeepDyve Pubget Overpricing